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Dysregulation of the complement alternative pathway (AP) is a major pathogenic mecha-
nism in atypical hemolytic-uremic syndrome (aHUS). Genetic or acquired defects in factor 
H (FH), the main AP regulator, are major aHUS drivers that associate with a poor prog-
nosis. FH activity has been suggested to be downregulated by homologous FH-related 
(FHR) proteins, including FHR-3 and FHR-1. Hence, their relative levels in plasma could 
be disease-relevant. The genes coding for FH, FHR-3, and FHR-1 (CFH, CFHR3, and 
CFHR1, respectively) are polymorphic and located adjacent to each other on human 
chromosome 1q31.3. We have previously shown that haplotype CFH(H3)–CFHR3*B–
CFHR1*B associates with aHUS and reduced FH levels. In this study, we used a specific 
enzyme-linked immunosorbent assay to quantify FHR-3 in plasma samples from con-
trols and patients with aHUS genotyped for the three known CFHR3 alleles (CFHR3*A, 
CFHR3*B, and CFHR3*Del). In the 218 patients carrying at least one copy of CFHR3, 
significant differences between CFHR3 genotype groups were found, with CFHR3*A/
Del patients having the lowest FHR-3 concentration (0.684–1.032 µg/mL), CFHR3*B/
Del and CFHR3*A/A patients presenting intermediate levels (1.437–2.201  µg/mL), 
and CFHR3*A/B and CFHR3*B/B patients showing the highest concentration (2.330–
4.056 µg/mL) (p < 0.001). These data indicate that CFHR3*A is a low-expression allele, 
whereas CFHR3*B, associated with increased risk of aHUS, is a high-expression allele. 
Our study reveals that the aHUS-risk haplotype CFH(H3)–CFHR3*B–CFHR1*B gene-
rates twofold more FHR-3 than the non-risk CFH(H1)–CFHR3*A–CFHR1*A haplotype. 
In addition, FHR-3 levels were higher in patients with aHUS than in control individuals 
with the same CFHR3 genotype. These data suggest that increased plasma levels of 
FHR-3, altering the balance between FH and FHR-3, likely impact the FH regulatory 
functions and contribute to the development of aHUS.
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inTrODUcTiOn
Atypical hemolytic-uremic syndrome (aHUS) is a thrombotic micro-
angiopathy characterized by hematological and renal alterations, 
although neurological and cardiovascular damage is also frequent 
(1, 2). Genetic and/or acquired defects in the complement alternative 
pathway that disturb the activation-regulation balance are present 
in 40–60% of patients, potentiating the initial endothelial damage 
in the microvasculature (3–5). The prognosis of patients with aHUS 
who have mutations in complement factor H (FH) is particularly 
poor and is associated with terminal renal insufficiency at disease 
onset and disease recurrence in the transplanted kidney (6).
Factor H is the main complement regulator in the fluid phase, 
and it also binds to autologous cellular surfaces to protect them from 
complement-mediated damage (7). The FH gene, CFH, is located 
within a gene cluster that includes five additional genes (CFHR1 to 
CFHR5) coding for the homologous FH-related proteins (FHR-1 
to FHR-5), which likely compete with FH for ligand binding and 
act as complement deregulators (8, 9). Several aHUS-predisposing 
genetic variants within the CFH/CFHR gene cluster have been 
found. A particular CFH haplotype named CFH(H3) increases 
aHUS penetrance in carriers and modulates the clinical phenotype 
(10–12), and the homozygous deletion of the CFHR3 and CFHR1 
genes (ΔCFHR3–CFHR1) predisposes patients to an autoimmune form of 
aHUS characterized by the generation of anti-FH blocking anti-
bodies (13–15). Additional aHUS-risk variants within the CFH/
CFHR region are the CFHR1*B and the CFHR3*B alleles (16, 17).
The molecular basis for the contribution of the genetic 
variants CFH(H3), CFHR3*B, and CFHR1*B to the pathogenic 
mechanism of aHUS have not yet been determined. These vari-
ants include non-synonymous single-nucleotide polymorphisms 
(SNPs) with potential functional consequences, but changes 
in gene expression cannot be excluded, particularly in the case 
of CFH(H3) and CFHR3*B, which include SNPs within their 
5′-untranslated region (UTR).
We have shown that the aHUS-risk haplotype CFH(H3) is 
nearly always associated with the CFHR3*B and CFHR1*B alleles, 
thus generating an extended CFH(H3)–CFHR3*B–CFHR1*B 
haplotype, which predisposes to aHUS and favors a poorer progres- 
sion of renal function at disease onset (17); we also demonstrated 
that patients homozygous for this haplotype have lower FH levels. 
To check the hypothesis that the aHUS-risk CFHR3*B allele (tagged 
by rs385390A; rs446868C; rs138675433C; rs149352569A) gives rise 
to higher protein levels than the non-risk CFHR3*A allele 
(rs385390C; rs446868A; rs138675433T; rs149352569T), we deter-
mined FHR-3 levels in patients with aHUS and in control individu-
als genotyped for CFHR3*A, CFHR3*B, and ΔCFHR3–CFHR1 (referred to 
as CFHR3*Del). By using an FHR-3-specific enzyme-linked immu-
nosorbent assay (ELISA) (18), we demonstrate that CFHR3*A is a 
low-expression allele and CFHR3*B is a high-expression allele and 
that increased FHR-3 levels in plasma are associated with aHUS.
MaTerials anD MeThODs
Patients and controls
A total of 230 patients from the Spanish aHUS registry with 
known CFH, CFHR3, and CFHR1 genotypes were selected for 
the study. Genotyping had been previously determined by direct 
sequencing and copy number variation analyzed by multiplex 
ligation-dependent probe amplification (MLPA) or by using an 
in-house comparative genomic hybridization microarray (19). 
Studies to identify mutations in complement genes had also been 
performed on most of these patients. Blood samples were drawn 
during an acute aHUS episode or during remission, centrifuged 
to obtain serum and ethylenediaminetetraacetic acid (EDTA) 
plasma, and stored at −80°C until use. Peripheral-blood leuko-
cytes (PBLs) were used to prepare genomic DNA by standard 
procedures. Plasma and DNA samples from 49 healthy Spanish 
individuals were also obtained and used in the study. Patients 
and controls provided written informed consent, as approved by 
the ethical committees from La Paz University Hospital or the 
Biological Research Center.
CFHR3 genotyping
Genotyping of the CFHR3*A and CFHR3*B alleles was performed 
by Sanger sequencing of CFHR3 exon 5, as described previously 
(17). The CFHR3–CFHR1 genomic deletion was analyzed by 
using the SALSA MLPA probemix P236-A3 ARMD mix-1 (MRC-
Holland, Amsterdam, Netherlands); this deletion is referred to as 
the CFHR3*Del allele, and it does not generate FHR-3 and FHR-1.
Fhr-3 Quantitation
FHR-3 levels in serum or EDTA plasma samples from the 230 
patients with aHUS and the 49 controls were determined by using 
a specific sandwich FHR-3 ELISA as described previously (18).
statistical analyses
The statistical significance of FHR-3 levels in the various geno- 
type or age groups was analyzed with IBM SPSS Software.
resUlTs
Fhr-3 levels in spanish controls suggest 
Differential expression of CFHR3*A  
and CFHR3*B
We had previously determined FHR-3 levels in serum samples 
from 100 Dutch controls and had shown that FHR-3 concentra-
tion correlated with the number of CFHR3 copies (18). We have 
now confirmed this observation in 47 Spanish control individuals 
containing 1 or 2 copies of CFHR3. FHR-3 levels ranged between 
0.14 and 1.16  µg/mL (mean 0.61 ±  2.40; 95% CI 0.54–0.68), 
and FHR-3 concentration in individuals with 2 copies doubled 
the concentration observed in individuals with only one copy 
(0.68 vs. 0.36  µg/mL, p <  0.0001). Interestingly, genotyping of 
the Spanish controls for the CFHR3*A and CFHR3*B alleles 
provided additional data. FHR-3 levels were significantly lower in 
individuals with the CFHR3*A/A genotype (0.55 ± 0.15 µg/mL) 
than in individuals with the CFHR3*A/B (0.78 ±  0.18  µg/mL; 
p  =  0.001) or CFHR3*B/B (0.82  ±  0.08  µg/mL; p  =  0.033) 
genotypes, thus suggesting a lower expression of the CFHR3*A 
allele. A plausible explanation for this finding is that genetic 
variants located within the 5′-UTR of CFHR3 exon 1 (rs385390 
and rs446868) determine a different expression of the CFHR3*A 
Table 1 | FHR-3 levels differ between CFHR3 genotype groups.
genotype N Mean sD se 95% confidence interval for mean Minimum Maximum
lower bound Upper bound
A/Del 24 0.85783 0.411379 0.083972 0.68412 1.03154 0.254 1.771
B/Del 32 1.82991 1.028643 0.182840 1.45904 2.20077 0.147 3.879
A/A 47 1.74011 1.033595 0.150765 1.43663 2.04358 0.124 4.443
A/B 58 2.70117 1.410761 0.185242 2.33023 3.07211 0.566 6.666
B/B 47 3.32538 2.487197 0.362795 2.59511 4.05565 0.481 13.450
Total 208 2.27832 1.722567 0.119438 2.04285 2.51379 0.124 13.450
SPSS Descriptives table from the analysis of FHR-3 levels (µg/mL) in 208 patients with atypical hemolytic uremic syndrome grouped by CFHR3 genotype. Statistically significant 
differences between the five CFHR3 genotype groups were found (Kruskal–Wallis test, p < 0.0001).
FigUre 1 | Genetic variants associated with the CFHR3*A and CFHR3*B alleles. (a) Exon–intron structure of the CFHR3 gene showing the location of the genetic 
variants within exon 1 (rs385390; rs446868) and exon 5 (rs138675433; rs149352569) that tag the CFHR3*A and CFHR3*B alleles. (b) In silico data of gene 
expression correlations from the GTExPortal show that individuals who are homozygous for the rs385390 A variant present lower mRNA expression in liver tissue 
than individuals homozygous for the rs385390 C variant, or than heterozygous individuals. Number of individuals with each genotype is shown between brackets. 
GTExPortal: Portal for the Genotype-Tissue Expression project (https://www.gtexportal.org). GTExPortal is supported by the Common Fund of the National 
Institutes of Health. The data in panel (b) were obtained on October 2017.
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and CFHR3*B alleles (Figure 1A). No data on the effect of these 
SNPs on CFHR3 expression could be obtained from the Gene 
Expression Omnibus and Human Protein Atlas databases. 
However, data on gene expression correlations for the CFHR3 
SNP rs385390 (c.1-90A>C) available at the GTExPortal showed 
lower mRNA levels of the A variant (tagging the CFHR3*A allele) 
than the C variant (tagging the CFHR3*B allele) in liver tissue 
(Figure 1B).
CFHR3*A is a low-expression allele,  
and CFHR3*B is a high-expression allele
To confirm the association between FHR-3 levels and the CFHR3*A 
and CFHR3*B alleles, we determined FHR-3 levels in 230 patients 
with aHUS of known CFHR3 genotypes (17). The 22 patients with 
aHUS with the CFHR3*Del/Del genotype presented minimal 
FHR-3 levels corresponding to the lower limit of detection of 
FigUre 2 | FHR-3 levels are associated with the CFHR3*A/B/Del genotypes. Boxplot of FHR-3 levels in 208 patients with atypical hemolytic uremic syndrome who 
were grouped according to their CFHR3 genotype; patients with the CFHR3 Del/Del genotype were not included because they have homozygous FHR-3 deficiency. 
The statistical significance obtained in pairwise two-sided multiple comparisons is also shown. Outliers in the CFHR3 A/B and B/B genotype groups are denoted by 
symbols (o).
Table 2 | The CFHR3*A allele generates lower FHR-3 levels than the CFHR3*B 
allele.
genotype Wilcoxon Z DscF value Pr > DscF
A/Del vs. B/Del −3.4935 4.9405 0.0043
A/Del vs. A/A −3.6041 5.0970 0.0029
A/Del vs. A/B −5.7174 8.0856 <0.0001
A/Del vs. B/B −5.9927 8.4749 <0.0001
B/Del vs. A/A 0.4694 0.6638 0.9901
B/Del vs. A/B −2.6552 3.7550 0.0608
B/Del vs. B/B −2.9811 4.2159 0.0240
A/A vs. A/B −3.6088 5.1036 0.0028
A/A vs. B/B −3.9435 5.5770 0.0008
A/B vs. B/B −0.8668 1.2258 0.9091
Results from pairwise two-sided multiple comparisons done by Dwass-Steel-Critchlow-
Fligner method. Pr > DSCF values lower than 0.05 denote statistically significant 
differences.
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H4b/H5/H6/H7/H8), CFHR3 (A/B/Del), and CFHR1 (A/B/Del) 
in these patients had already been performed [(17); Table S1 
in Supplementary Material]. As many as 63 different CFH–
CFHR3–CFHR1 genotype combinations were observed (Table 
S2 in Supplementary Material), but only 23 of them were found 
in 3 or more patients (Table 3). The CFHR3*Del/Del genotype 
the ELISA. The other 208 patients, presenting CFHR3 genotypes 
A/Del, B/Del, A/A, A/B, or B/B, showed a vast range of FHR-3 
concentrations (0.124–13.450  µg/mL; mean 2.278  ±  1.723) 
(Table 1). Statistical analyses of these data were performed with 
nonparametric tests. The Kruskal–Wallis H test showed that 
there was a statistically significant difference in FHR-3 levels 
between the five CFHR3 genotypes [χ2(4) = 53.568; p < 0.001]. 
Next, a pairwise two-sided multiple comparison analysis was 
performed using the Dwass-Steel-Critchlow-Fligner method. 
Significant differences between the A/Del and B/Del genotypes 
(p =  0.0043), as well as between the A/A and B/B genotypes 
(p  =  0.0008) were found, thus revealing that the CFHR3*A 
allele was associated with lower FHR-3 concentrations than the 
CFHR3*B allele (Table 2; Figure 2).
Fhr-3 levels and genetic background
Statistical analyses showed that plasma FHR-3 levels were 
associated with the CFHR3*A/B/del genotypes; however, protein 
levels within each CFHR3 genotype group showed great variation. 
To explore the possibility that CFHR3 gene expression was also 
modulated by genetic factors in the adjacent CFH and CFHR1 
genes, we analyzed the CFH–CFHR3–CFHR1 genotypes of the 
230 patients with aHUS. Genotyping of CFH (H1/H2/H3/H4a/
5Pouw et al. Complement FHR-3 Levels and aHUS
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is associated with three CFH genotypic variants (H4a, H4b, or 
H2), and 90% of patients with CFHR3*A/Del or CFHR3*B/Del 
present 1 out of 4 different CFH–CFHR3–CFHR1 genotypes. 
Greater heterogeneity was found in the CFHR3*A/A and 
CFHR3*A/B groups, whereas 75% of the CFHR3*B/B patients 
were found to carry only two different CFH-CFHR3-CFHR1 
genotypes. However, when comparing FHR-3 levels within 
each CFHR3 genotype group, no statistically significant differ-
ences between CFH–CFHR3–CFHR1 genotypes were found, 
suggesting that genetic variants in CFH and CFHR1 do not 
substantially contribute to the expression of the CFHR3*A and 
CFHR3*B alleles.
From the data in Table 3, we can also conclude that the CFHR3* 
Del allele mostly presents in the CFH(H4a) and CFH(H4b) haplo-
types, the CFHR3*A allele in the CFH(H1) and CFH(H2) haplotypes 
and the CFHR3*B allele in the CFH(H3) and CFH(H8) haplotypes. 
These conclusions were further supported by the inferred CFH–
CFHR3–CFHR1 haplotypes. Among the 208 patients expressing 
FHR-3 (groups G2–G6 in Table 3), 150 patients had CFH–CFHR3–
CFHR1 genotypes homozygous for at least two genes, thus allowing 
segregation of the corresponding CFH–CFHR3–CFHR1 chromo-
somes. Some 25 different CFH–CFHR3–CFHR1 haplotypes were 
observed, the most frequent being CFH(H3)–CFHR3*B–CFHR1*B 
(31.7%), CFH(H4a)–CFHR3*Del–CFHR1*Del (20%) and CFH(H1)–
CFHR3*A–CFHR3*A (16.3%). An analysis of FHR-3 levels in 
patients homozygous or hemizygous for these haplotypes rev- 
ealed higher expression in those patients with the CFH(H3)–
CFHR3*B–CFHR1*B than CFH(H1)–CFHR3*A–CFHR3*A  
haplotype (1.87 ± 1.36 µg/mL vs. 0.9 ± 0.43 µg/mL; Kruskal–Wallis 
test, p < 0.001).
FHR-3 levels were also higher in patients with mutations in the 
complement genes CFH, CFI, MCP, C3, or CFB, than in patients 
without mutations (2.52 ± 1.62 vs. 2.06 ± 1.44 µg/mL, p < 0.05). 
This difference is probably explained by the different frequency 
of the CFHR3*B allele in patients with mutations (79%) and 
without mutations (59%).
Fhr-3 levels are higher in Patients With 
ahUs Than in controls With the same 
CFHR3 genotype
Having observed that FHR-3 levels are associated with CFHR3* 
A/B/Del genotypes, we then compared FHR-3 levels in control 
individuals and in patients with aHUS with the same CFHR3 
genotype. FHR-3 levels were significantly higher in the patients 
with aHUS than in the controls with the same CFHR3 genotypes 
A/Del, A/A or A/B, whereas in the CFHR3 genotypes B/Del and 
B/B the differences in FHR-3 levels were not significant due to 
the small sample size of the control cohort (Figure  3). These 
results suggest that factors other than the CFHR3*A/B/Del alleles 
Table 3 | CFH–CFHR3–CFHR1 genotypes and FHR-3 levels.
CFH–CFHR3–CFHR1genotypea Fhr-3 (µg/ml) number of patients Frequencyb (%)
CFH CFHR3 CFHR1 Mean sD
G1 (22) H4a,H4b Del/Del Del/Del 0.011 0.003 9 40.9
H4a,H4a Del/Del Del/Del 0.010 0.000 7 31.8
H2,H4a Del/Del Del/Del 0.022 0.024 4 18.2
G2 (24) H2,H4a A/Del B/Del 0.784 0.363 7 29.2
H1,H4b A/Del A/Del 0.778 0.444 6 25.0
H1,H4a A/Del A/Del 0.719 0.418 5 20.8
G3 (32) H3,H4a B/Del B/Del 2.155 0.862 15 46.9
H3,H4b B/Del B/Del 1.872 0.981 7 21.9
H3,H2 B/Del B/Del 0.871 1.066 4 12.5
H3,H4a B/Del A/Del 2.702 0.346 3 9.4
G4 (47) H1,H1 A/A A/A 1.871 0.867 12 25.5
H1,H2 A/A A/B 1.584 0.907 11 23.4
H1,H2 A/A A/A 2.297 1.152 4 8.5
H1,H5 A/A A/A 2.360 0.988 3 6.4
H2,H2 A/A B/B 1.679 2.397 3 6.4
H2,H7 A/A A/B 1.152 0.516 3 6.4
G5 (58) H1,H3 A/B A/B 2.445 1.171 17 29.3
H2,H3 A/B B/B 2.310 1.218 12 20.7
H2,H3 A/B A/B 3.241 0.749 6 10.3
H3,H4a A/B B/B 2.889 1.226 3 5,2
H1,H8 A/B A/B 3.337 3.003 3 5.2
G6 (47) H3,H3 B/B B/B 3.673 3.048 28 59.6
H3,H8 B/B B/B 3.547 0.909 7 14.9
CFH and CFHR1 variants observed in patients with atypical hemolytic uremic syndrome presenting one or two copies of the CFHR3*A/B/Del alleles. Genotypes are ordered 
according to their relative frequency within the respective CFHR3 genotype subgroup (G1 to G6). FHR-3 levels within each CFH–CFHR3–CFHR1 genotype subgroup are also 
shown.
aMinor CFH–CFHR3–CFHR1 genotypes (i.e., those observed in 1 or 2 patients) are not included in the table.
bFrequency of each CFH–CFHR3-–CFHR1 genotype within the corresponding subgroup (G1–G6); the total number of patients is shown between brackets.
FigUre 3 | FHR-3 levels are higher in patients with atypical hemolytic uremic syndrome (aHUS) than in controls. Histogram showing the mean FHR-3 levels in 
controls and in patients with aHUS with different CFHR3 genotypes. Statistically significant differences (Kruskal–Wallis test, p < 0.05) are denoted by an asterisk. 
Dashed lines indicate the highest FHR-3 level observed in controls and patients.
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contribute to FHR-3 levels. To determine whether FHR-3 levels 
change with age, all patients with aHUS and at least one copy of 
CFHR3 were included in one of three subgroups, according to 
their age at blood sampling. No significant differences in FHR-3 
concentration were observed when comparing all the patients 
together, or when they were further subdivided according to their 
CFHR3 genotype (Figure 4).
DiscUssiOn
In this study, we show that the aHUS-risk CFHR3*B allele deter-
mines higher FHR-3 levels than the non-risk CFHR3*A allele. 
This observation was anticipated by the analysis of 49 healthy 
Spanish controls genotyped for the CFHR3*A/B/Del alleles and 
was further demonstrated in 230 patients with aHUS, most of 
Spanish origin.
FHR-3 levels in the 49 Spanish controls were 0.58 ± 0.26 µg/mL, 
which was very similar to the 0.69 µg/mL previously determined 
in 100 Dutch controls (18). In fact, these results support the 
evidence indicating that the actual concentration of FHR-3 
in plasma is indeed much lower than the initial estimation of 
FHR-3 levels at 70–100 µg/mL (20). Moreover, we observed that 
the FHR-3 levels were significantly higher in the aHUS patients 
than in the control individuals (2.06 ± 1.77 vs. 0.58 ± 0.26 µg/mL, 
p < 0.0001). This result was not due to a significant difference in 
the allele frequency of CFHR3*Del between patients and controls, 
because when the 22 aHUS patients and the 2 controls with the 
CFHR3*Del/Del genotype and homozygous FHR-3 deficiency 
were excluded, a similar difference in FHR-3 levels was observed 
(2.28 ± 1.72 vs. 0.61 ± 0.24 µg/mL, p < 0.0001).
These results suggest that increased FHR-3 levels predispose 
to aHUS. This observation is in line with a previous study 
(21) that determined FHR-3 levels in 21 patients with aHUS 
(1.60  ±  0.57  µg/mL) and 21 controls (1.06  ±  0.53  µg/mL), 
although the difference in FHR-3 levels between their patient and 
control cohorts was smaller than in our study, which could well 
be related to the cohort size and the variation in allele frequency. 
In our study, 4% of the controls and 9% of the patients with 
aHUS carried the CFHR3*Del/Del genotype (i.e., homozygous 
CFHR3-CFHR1 deletion), frequencies comparable to the 2.9% 
and 12.4% observed in a French study comparing 70 controls and 
117 patients with aHUS (22). However, in the study by Schäfer 
FigUre 4 | FHR-3 levels in patients with atypical hemolytic uremic syndrome (aHUS) do not change with age. (a) Boxplot of FHR-3 levels in 198 aHUS patients 
with the CFHR3 genotypes A/Del, B/Del, A/A, A/B, or B/B, subgrouped according to their age at blood sampling (in years). (b–F) Boxplots of FHR-3 levels in each 
of the five CFHR3 genotype groups. The number of patients within each age subgroup is also shown. Outliers are denoted by symbols (o).
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et al. (Table S2 in Supplementary Material), as many as 14% of 
controls and 38% of patients with aHUS presented homozygous 
deficiency of FHR-3, and these high and very different frequen-
cies limit the relevance of their observations when comparing 
aHUS patients and controls. High frequencies of homozygous 
CFHR3–CFHR1 deletion have been reported in aHUS patients 
with anti-FH autoantibodies or with mutations in complement 
factor I (22), as well as in Middle Eastern and North African 
control populations (23, 24); the reason for the high frequency 
of the homozygous CFHR3-CFHR1 deletion in certain control 
populations could be related with its protective role against age-
related macular degeneration (25) and IgA nephropathy (26). In 
conclusion, the comparison of FHR-3 levels could be biased by 
the ethnic origin of controls and patients, and by the frequency 
of anti-FH autoantibodies or factor I mutations in the patient 
cohorts. These facts have to be taken into account when trying 
to establish proper comparisons between control and patient 
cohorts.
To adequately analyze the contribution of the CFHR3*A and 
CFHR3*B alleles to FHR-3 levels, patients and controls with the 
CFHR3*Del/Del genotype were excluded. An analysis of the 
control cohort suggested a higher expression of the CFHR3*B 
allele that was clearly confirmed in the aHUS cohort. Patients 
with the CFHR3*A/Del genotype showed the lowest FHR-3 
levels (0.684–1.032 µg/mL), patients with genotypes B/Del and 
A/A presented intermediate levels (1.437–2.201  µg/mL), and 
patients with genotypes A/B and B/B had the highest FHR-3 
levels (2.330–4.056 µg/mL), explaining the wide individual range 
in FHR-3 concentrations between 0.684 and 4.056 µg/mL.
More importantly, statistically significant differences in 
FHR-3 levels were observed between the CFHR3 genotypes A/Del  
and B/Del (p =  0.0043), A/A and A/B (p =  0.0028), and A/A 
and B/B (p = 0.0008), demonstrating that the CFHR3*A allele is 
associated with lower FHR-3 concentrations than the aHUS-risk 
CFHR3*B allele. These data provide a genetic explanation for the 
increased FHR-3 levels observed in patients with aHUS, who 
present a higher frequency of the CFHR3*B allele than control 
individuals. However, whether higher FHR-3 levels increase 
susceptibility to aHUS is currently unknown, and the potential 
pathogenic mechanism will remain elusive until the actual physi-
ological role of FHR-3 within the complement system is fully 
understood.
Recombinant FHR-3 binds C3b and C3d with similar 
affinity to FH (27); once bound, however, it cannot regulate 
complement activation because it lacks domains homologous 
to the N-terminal region of FH (28, 29). Therefore, increased 
competition between FHR-3 and FH for C3b binding will 
theoretically result in reduced complement regulation. Because 
the molar FHR-3 concentration in plasma is approximately 140 
times lower than the molar FH concentration (18), competition 
between FHR-3 and FH for plasma-C3b binding is likely to be 
irrelevant. Nevertheless, the FHR-3/FH ratio could be more 
relevant for appropriate regulation of complement activation on 
cellular surfaces, such as the damaged endothelium of patients 
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with aHUS. A recent study (30) shows a 1.3–1.9 increase in the 
FHR-1/FH molar ratio in patients with IgA nephropathy with 
disease progression. In our study, FHR-3 levels are 3.6 times 
higher in aHUS than in controls, while FH levels are only 1.2 
times higher (not shown), but to demonstrate whether the 
increased FHR-3/FH ratio actually reduces complement regula-
tion on the endothelial surface will require further investigation. 
Indirect evidence for competition between FH and FHR-3 on the 
cellular surface is provided by the functional characterization of 
a FH:FHR-3 hybrid protein identified in a familial case of aHUS 
(31). The authors suggest that the loss of FH regulatory activity 
of the hybrid FH:FHR-3 protein on cell-based assays could be 
explained because its C-terminal domains (belonging to FHR-3) 
prevent the correct orientation and function of the N-terminal 
domains (belonging to FH). A slightly different FH:FHR-3 
hybrid protein, which also shows reduced FH regulatory activity 
on the cellular surface, has been reported in a sporadic case of 
aHUS (32). Based on these findings, we speculate that inefficient 
complement regulation on the cellular surface could also result 
from an altered FH/FHR-3 ratio. This would explain why the 
CFH(H3)–CFHR3*B–CFHR1*B haplotype, associated with 
reduced FH levels (17) and enhanced FHR-3 levels (this study) 
increases the risk of aHUS. The CFH(H3)-CFHR3*B–CFHR1*B 
haplotype also carries the CFH (rs1065489; p936D<E) and 
CFHR3 variants (rs385390, rs426736, and rs371075) that were 
shown to confer protection against meningococcal disease (33); 
quantitation of FHR-3 levels and CFHR3*A/B/Del genotyping 
in these patients will likely help establish the actual relationship 
between this haplotype and protection against N. meningitidis 
infection.
Another interesting conclusion from our study is that FHR-3 
concentration is not only determined by the number of copies 
of the CFHR3*A and CFHR3*B alleles. Stratification by the 
CFHR3*A/B/Del genotype still showed higher FHR-3 levels 
in patients with aHUS than in controls (Figure  3), suggesting 
that additional genetic and/or acquired factors contribute to 
the increased FHR-3 concentration in patients with aHUS. We 
cannot rule out the possibility that genetic variants within the 
adjacent CFH and CFHR1 genes modulate CFHR3 expression, 
but our current results do not favor this hypothesis (Table  3). 
Because plasma levels of FH have a wide range of variation and 
were shown to increase with age (34), we explored whether this 
was also the case for FHR-3 levels by analyzing data from the 
patients with aHUS. FHR-3 levels remain unchanged in the 
three age subgroups, either when considering the whole patient 
cohort, or when each CFHR3 genotype was analyzed separately 
(Figure  4). A similar result was observed in the two age sub-
groups from the control cohort, but the small sample size and 
the absence of pediatric controls limit the relevance of this obser-
vation. Although FHR-3 does not appear to be an acute phase 
reactant (18), FHR-3 levels in patient samples could be associ-
ated with disease activity, in particular with the decreased renal 
function observed in aHUS. In this context, two recent studies in 
IgA nephropathy patients suggest that impaired renal function 
increases the FHR-1/FH ratio (30, 35). To fully understand the 
increased FHR-3 levels observed in patients with aHUS, it would 
be necessary to monitor FHR-3 concentration in serial samples 
from patients along their clinical evolution, and renal function/
damage over time.
In conclusion, in this study we show that CFHR3*A is a 
low-expression allele, and CFHR3*B is a high-expression allele, 
and that, next to CFHR3 copies, other genetic factors determine 
the FHR-3 levels. We also show that the aHUS-risk CFH(H3)–
CFHR3*B–CFHR1*B haplotype is associated with increased 
FHR-3 levels, and speculate that it leads to an imbalance 
between the local FH and FHR-3 concentration that predisposes 
patients to aHUS. These results uncover that genotyping for the 
CFHR3*A, CFHR3*B, and CFHR3*Del alleles is necessary for a 
proper interpretation of FHR-3 levels within a certain pathologi-
cal context, and we propose to incorporate these analysis to the 
current genetic workflow in aHUS patients.
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